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To test the hypothesis that age-related macular degeneration (AMD) and retinal microvascular
signs are differentially associated with lobar and deep cerebral microbleeds (CMBs).
Methods
CMBs in lobar regions indicate cerebral amyloid angiopathy (CAA). β-Amyloid deposits are
implicated in both CAA and AMD. Deep CMBs are associated with hypertension, a major risk
factor for retinal microvascular damage. This population-based cohort study included 2,502
participants in the Age, Gene/Environment Susceptibility (AGES)-Reykjavik Study who un-
dertook binocular digital retinal photographs at baseline (2002–2006) to assess retinal micro-
vascular signs and AMD and brain MRI scan at both baseline and follow-up (2007–2011) to
assess CMBs. We assessed retinal microvascular lesion burden by counting the 3 retinal mi-
crovascular signs (focal arteriolar narrowing, arteriovenous nicking, and retinopathy) concur-
rently present in the participant. We used multiple logistic models to examine the association of
baseline retinal pathology to incident CMBs detected at follow-up.
Results
During an average 5.2 years of follow-up, 461 people (18.3%) developed new CMBs, including
293 in exclusively lobar regions and 168 in deep regions. Pure geographic atrophy was signifi-
cantly associated with strictly lobar CMBs (multivariable-adjusted odds ratio 2.59, 95% confi-
dence interval [CI] 1.01–6.65) but not with deep CMBs. Concurrently having ≥2 retinal
microvascular signs was associated with a 3-fold (95% CI 1.73–5.20) increased likelihood for
deep CMBs but not exclusively lobar CMBs.
Conclusions
Retinal microvascular signs and pure geographic atrophy may be associated with deep and
exclusively lobar CMBs, respectively, in older people. These results have implications for further
research to define the role of small vessel disease in cognitive impairment.
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Glossary
AD=Alzheimer disease;AGES=Age,Gene/Environment Susceptibility;AMD= age-relatedmacular degeneration;BMI= body
mass index;CAA = cerebral amyloid angiopathy;CMB = cerebral microbleed; SVD = small vessel disease;WML = white matter
lesion.
Cerebral microbleeds (CMBs) are a neuroimaging marker of
cerebral small vessel disease (SVD) and are associated with
stroke, cognitive decline, and dementia.1–3 Histopathologically,
CMBs on T2*-weightedMRI correspond to small perivascular
hemosiderin deposits.1 It has been assumed that CMBs in the
deep or infratentorial areas reflect hypertensive micro-
angiopathy, whereas lobar CMBs represent a marker for ce-
rebral amyloid angiopathy (CAA).1,4
Microvasculature in the retina and the brain shares embryo-
logic origin, anatomic features, metabolic activities, and similar
patterns of vascularization and extracellular deposits.5 Retinal
microvascular signs (e.g., focal arteriolar narrowing and arte-
riovenous nicking) are thought to result partly from short- or
long-term exposures to cardiovascular risk factors, especially
hypertension.6 Population-based cohort studies have related
retinal microvascular signs to white matter lesions (WMLs),
lacunar infarcts, and subcortical infarcts.7–9 However, the lon-
gitudinal association of retinal microvascular pathology with
CMBs by location has yet to be examined.
Age-related macular degeneration (AMD) is a common retinal
degenerative disorder among older people. Evidence has emerged
that β-amyloid deposits, a hallmark of Alzheimer disease (AD),
may be involved in the pathogenesis of AMD.10,11 Thus, retinal
amyloid plaque has been proposed as a potential biomarker for
AD and amyloid deposits in the brain.12–14
The cross-sectional data from the population-based Age,
Gene/Environment Susceptibility (AGES)-Reykjavik Study
showed an association of CMBs with retinal microvascular
signs15 and a suggestive association with pure geographic at-
rophy.16 In this follow-up study, we seek to investigate the
longitudinal associations of retinal microvascular signs and
AMD with CMBs at specific locations in the brain. We hy-
pothesize that the load of retinal microvascular signs is asso-
ciated specifically with deep CMBs due primarily to
hypertensive microangiopathy, whereas AMD is associated
with lobar CMBs due predominantly to CAA.
Methods
Study population
This is a longitudinal population-based cohort study. Partic-
ipants were from the AGES-Reykjavik Study that aimed at
investigating genetic and environmental factors contributing to
clinical and subclinical diseases in aging, as fully described
elsewhere.17 Briefly, the Reykjavik Study was launched in 1967
by the Icelandic Heart Association and included a cohort of
men and women born from 1907 to 1935. In 2002 to 2006,
survivors of the cohort were invited to participate in the AGES-
Reykjavik Study, and 5,764 persons were examined (baseline,
AGES-I). In 2007 to 2011, survivors of the AGES-I cohort
were invited for follow-up examination, and 3,316 were reas-
sessed (follow-up, AGES-II). In total, 2,672 persons un-
derwent brain MRI scans in both AGES-I and AGES-II and
had the brain images needed for assessment of CMBs.18 Of
these, we excluded 133 persons who had no data of either
AMD or retinal vascular signs and additional 37 individuals
who were diagnosed with prevalent dementia at baseline,
leaving 2,502 persons for the present analysis. Of these, data on
AMD and retinal microvascular signs were available in 2,484
and 2,497 persons, respectively.
Standard protocol approvals, registrations,
and patient consents
The AGES-Reykjavik Study was approved by the Icelandic
National Bioethics Committee (VSN-00-063), which acts as
the Institutional Review Board of the Icelandic Heart Associ-
ation, and by the Institutional Review Board for the National
Institute on Aging, NIH. Written informed consent was
obtained from all participants.
Fundus photography and assessments
Digital fundus photographs were taken at baseline
(2002–2006) following standardized protocols.19 Briefly, after
the maximal pharmacologic dilation of the pupils, two 45°
retinal images, centered on the optic disc and the fovea, were
taken of each eye with a 6.3-megapixel Canon digital non-
mydriatic camera (Canon, Lake Success, NY). EyeQ Lite
software (an image-processing database for storage, retrieval,
and manipulation of digital retinal images) was used for retinal
image acquisition, assessment, and archiving.
Using the modified Wisconsin Age-Related Maculopathy Grad-
ing scheme, graders masked to participants’ identity evaluated
digital retinal images at the University of Wisconsin Ocular
Epidemiology Reading Center for AMD lesions.19 Early AMD
was defined by the presence of any soft drusen and pigmentary
abnormalities or the presence of large soft drusen. Late AMD
was defined by the presence of either geographic atrophy or
signs of exudativeAMD(i.e., subretinal hemorrhage, subretinal
fibrous scar, retinal pigment epithelial detachment, sensory
retinal detachment, and any signs of treatment for neovascular
AMD). Reassessments on randomly selected images of 25 eyes
showed excellent intraobserver (κ = 0.82–1.0) and in-
terobserver (κ = 0.88–1.0) agreement on AMD classification.19
Retinal microvascular signs were assessed following a validated
protocol.20 Retinal focal arteriolar narrowing or arteriovenous
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nicking was defined as present if the grader was at least 90%
certain that the lesion was present in a given eye. Retinopathy
lesions, classified similarly, included retinal blot hemorrhages,
microaneurysms, soft exudates, and more advanced lesions
associated with diabetic retinopathy. The intraobserver and
interobserver agreement was fair to good (κ = 0.31–0.76) for
focal arteriolar signs and excellent (κ = 0.81–1.00) for reti-
nopathy lesions.21
MRI acquisition and reading protocol
All eligible participants had high-resolution brain MRI ac-
quired on a 1.5T Signa TwinSpeed System (General Electric
Medical Systems, Waukesha, WI) at both the AGES-I and
AGES-II examinations.18,22 Briefly, the core protocol included
a T1-weighted 3-dimensional spoiled gradient-echo sequence,
a proton density/T2-weighted fast spin-echo sequence, a fluid-
attenuated inversion recovery sequence, and a T2*-weighted
gradient-recalled echo sequence. MRI scan parameters for all
sequences are fully reported elsewhere.15,22 All images were
acquired to give full brain coverage, and slices were angled
parallel to the anterior commissure-posterior commissure line
to give reproducible image views in the oblique-axial plane.
All brain images were analyzed automatically with the AGES/
Montreal Neurological Institute image postprocessing pipe-
line,22 which segments the whole brain into gray matter, nor-
mal white matter,WMLs, and CSF. Brain infarcts were defined
as defects in the brain parenchyma with a signal intensity that
was isointense to that of CSF on all sequences with a diameter
≥4 mm, except for infarcts in the cerebellum, brainstem, and
cortex, which had no size criteria.21
Assessment and categorization of CMBs
CMBs were defined as a focal area of signal void within the
brain parenchyma that is visible on the T2*-weighted gradient-
recalled echo images and smaller or invisible on T2-weighted
images. The semiquantitative assessment of CMBs is con-
ducted at a computer workstation with customized in-house
software for the longitudinal image analysis. To maximize
comparability of baseline and follow-up images, they were
aligned with each other with a linear coregistration and viewed
side by side on the computer screen. This involved registering
both the baseline and follow-up proton density/T2-weighted,
T2*-weighted, and fluid-attenuated inversion recovery images
for each participant to the baseline T1-weighted 3-dimensional
spoiled gradient-echo images because the T1s had the highest
spatial resolution of all images in the protocol. By performing
this coregistration, we removed differences in image slice
alignments due to different positioning of the participant in the
head coil and different positioning of slices by the operator of
the MRI scanner at the time of scanning in the 2 visits. The
follow-up MRI scans were read by investigators blinded to the
baseline scans. If a CMBwas found on the follow-upMRI scan,
the baselineMRI scan was examined to determine whether the
CMB was present in the same location of the slice. If so, the
follow-up CMB was labeled prevalent; if not, the CMB was
labeled incident. This image preprocessing and rating
procedure made it possible to reliably distinguish incident
CMBs from prevalent CMBs. Both the intrarater agreement
and interrater agreement based on 2 ratings within a 6-month
interval were good (κ range 0.70–0.75).18
CMB location was recorded for lobar (frontal, temporal, pa-
rietal, and occipital) and deep or infratentorial (basal ganglia,
thalamus, corpus callosum, brainstem, and cerebellum)
regions. Because we were interested in CMBs with an amyloid
(CAA) or vascular (hypertensive microangiopathy) origin
according to our hypothesis and because it is possible that
lobar CMBs are also related to hypertension, we classified
people with CMBs by location as follows: people with at least 1
new CMB restricted to lobar regions were considered to have
lobar CMBs exclusively, and those with CMBs in a deep or
infratentorial region with or without concomitant lobar CMBs
were classified as having deep CMBs.2,18
Potential confounders
Demographics, cardiovascular risk factors, ischemic cerebral
SVD, and APOE genotype at baseline may confound the as-
sociation between retinal signs and incident CMBs. Age, sex,
education, and smoking were assessed via questionnaire ad-
ministered by a trained interviewer.17 Body mass index (BMI)
was calculated from measured weight (kilograms) divided by
height (meters) squared. Fasting blood glucose and total
cholesterol were measured according to standard protocols.
Use of medications (e.g., antihypertensive and hypoglycemic
agents) was ascertained from medication vials brought to the
study center. Arterial blood pressure was measured twice in
a sitting position to the nearest 2 mm Hg with a mercury
sphygmomanometer with a standard-sized cuff. Hypertension
was defined as having a self-reported history of hypertension,
having a blood pressure ≥140/90 mm Hg, or using antihy-
pertensive drugs. Diabetes mellitus was defined according to
self-reported history of diabetes mellitus, use of hypoglycemic
drugs, insulin injection, or fasting blood glucose level
≥7.0 mmol/L.15 APOE genotype was determined with stan-
dard DNA amplification and restriction isotyping.23
Statistical analysis
Baseline characteristics of participants were presented by in-
cident CMBs detected at follow-up. General linear or logistic
regression analysis was performed to compare means or pro-
portions with adjustment for age and sex. To assess the ex-
tensity and severity of retinal vascular lesions, we created an
index for retinalmicrovascular burden by counting the 3 retinal
microvascular signs concurrently present in the participant
(range 0–3), i.e., retinal focal arteriolar narrowing, arteriove-
nous nicking, and retinopathy lesions.24 The index was cate-
gorized into 0 (reference), 1, and ≥2; we combined the index
scores of 2 and 3 because of the low number of participants
who had a score of 3 (n = 9).We used binomial logistic models
to estimate the odds ratio and 95% confidence interval of
incident CMBs associated with AMD and the index of retinal
microvascular signs. Multinomial logistic regression models
were constructed to examine the association between retinal
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signs and CMBs by location (deep vs strictly lobar areas).2,18
We reported themain results from themodel that was adjusted
for age, sex, types of coil, follow-up interval, current smoking,
BMI, systolic blood pressure, use of antihypertensive medi-
cations, total cholesterol, diabetes mellitus, MRI markers of
cerebral SVD (i.e., subcortical infarcts, volume of WMLs, and
prevalent CMBs) assessed at baseline, and APOE e4 allele.
Stata Release 12 (StataCorp 2011, StataCorp LP, College
Station, TX) was used for all analyses.
Results
Baseline characteristics of participants
At baseline, the mean age of the 2,502 participants was 74.6
(SD = 4.7) years, and 58.63% were women. After an average
5.2 (SD = 0.2) years of follow-up, new CMBs were detected in
461 (18.43%) persons; of these, 293 (63.56%) had CMBs
exclusively in lobar regions and 168 (36.44%) in deep brain
regions. Compared with persons who did not develop new
CMBs at follow-up, those who developed incident CMBs were
older; were more likely to be male, smoke, and have diabetes
mellitus; and had a lower BMI, a higher level of diastolic blood
pressure, and a larger volume of WMLs, subcortical infarcts,
and prevalent CMBs at baseline (all p < 0.05), but the 2 groups
did not differ significantly in educational attainments, systolic
blood pressure, hypertension, use of antihypertensive drugs,
total cholesterol, and APOE e4 allele (table 1).
AMD subtypes and CMBs by anatomic location
At baseline, of the 2,484 persons, early AMD was detected in
451 (18.16%) and late AMD in 92 (3.70%); 63 (2.54%) of
those with late AMD had exudative AMD, and 29 (1.12%) had
pure geographic atrophy. After adjustment for multiple po-
tential confounders, including baseline MRI markers of cere-
bral SVD (e.g., prevalent CMBs, subcortical infarcts, and
volume ofWMLs), early AMDwas not significantly associated
with global or regional incident CMBs (table 2). However,
pure geographic atrophy, but not exudative AMD, was signif-
icantly associated with an ≈2.5-fold increased likelihood of
developing new CMBs exclusively in the lobar areas. Neither
exudative AMD nor pure geographic atrophy was significantly
associated with deep CMBs (table 2).
Retinal microvascular signs and CMBs by
anatomic location
After controlling for multiple potential confounders, including
baseline imaging markers of cerebral SVD, having retinal focal
arteriolar narrowing and arteriovenous nicking was signifi-
cantly associated with an increased likelihood of developing
new CMBs specifically in the deep brain areas, not exclusively
in the lobar regions (table 3). The presence of retinopathy
Table 1 Baseline characteristics of study participants by incident CMBs detected at the follow-up examination
Characteristics Total sample (n = 2,502)a
Incident CMBs detected at follow-up
No (n = 2,041) Yes (n = 461) p Valueb
Age, y 74.6 (4.7) 74.4 (4.7) 75.3 (5.0) 0.001
Female, n (%) 1,467 (58.6) 1,233 (60.4) 234 (50.8) <0.001
Elementary school, n (%) 486 (19.5) 401 (19.7) 85 (18.5) 0.656
Current smoking, n (%) 273 (10.9) 205 (10.0) 68 (14.8) 0.001
BMI, kg/m2 27.2 (4.1) 27.3 (4.2) 26.8 (4.0) 0.038
Diabetes mellitus, n (%) 230 (9.2) 174 (8.5) 56 (12.2) 0.029
Hypertension, n (%) 1,933 (77.3) 1,571 (77.0) 362 (78.5) 0.720
Systolic pressure, mm Hg 141.1 (19.7) 140.6 (19.0) 143.0 (19.8) 0.106
Diastolic pressure, mm Hg 74.2 (9.3) 74.0 (9.1) 75.4 (9.9) 0.011
Use of antihypertensive drugs, n (%) 1,505 (60.2) 1,228 (60.2) 277 (60.1) 0.826
Total cholesterol, mmol/L 5.65 (1.13) 5.67 (1.13) 5.59 (1.13) 0.862
Total volume of WMLs, mL 11.7 (6.6–21.8) 11.0 (6.3–20.0) 17.0 (9.1–29.8) <0.001
Subcortical infarcts 185 (7.4) 133 (6.5) 52 (11.3) 0.004
Prevalent CMBs, n (%) 426 (17.0) 296 (14.5) 130 (28.2) <0.001
APOE «4 allele, n (%) 648 (26.0) 513 (25.2) 135 (29.3) 0.060
Abbreviations: BMI = body mass index; CMB = cerebral microbleed; WML = white matter lesion.
Values are mean (SD) or n (%), except total volume of WMLs, which is median (interquartile range).
a This number included participants with measurement of either age-related macular degeneration (n = 2,484) or retinal microvascular signs (n = 2,497).
b P value was adjusted for age and sex except the test of age or sex difference.
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lesions was significantly associated with an increased likelihood
of having global CMBs.When the 3 retinal microvascular signs
were aggregated into a composite index, we found that, com-
pared to persons having none of the 3 retinal microvascular
signs, each additional lesion was associated with a significantly
increased likelihood of developing new CMBs globally (p for
trend = 0.047), especially in deep brain regions (p for trend
<0.001); concurrently possessing ≥2 retinal microvascular
signs was significantly associated with a 3-fold increased like-
lihood of developing deep CMBs, whereas there was no sig-
nificant association between the index of retinal microvascular
signs and the likelihood of having strictly lobarCMBs (table 3).
Additional analyses
First, we repeated the analyses by excluding persons with
prevalent CMBs at baseline (n = 427), which yielded results
similar to those reported in tables 2 and 3 (table e-1,
http://links.lww.com/WNL/A18). Furthermore, there was
no significant association between AMD and exclusively deep
CMBs, and the associations of retinal microvascular signs
(individual signs or the composite index) with exclusively deep
CMBs were less evident compared to those associations with
the presence of any deep CMBs (data not shown). Finally,
therewas no statistical interaction ofAPOE e4 allele with either
retinal vascular signs or AMD for incident CMBs, and analysis
stratified by APOE e4 did not show any additional significant
associations between retinal signs and incident CMBs (data
not shown).
Discussion
In a well-established cohort of older adults, we found evidence
suggesting that pure geographic atrophy might be associated
with an increased risk of developing CMBs exclusively in lobar
areas but not in deep brain regions. Early AMD and exudative
AMD were not associated with developing CMBs. In contrast,
a greater number of retinal microvascular signs was associated
with a higher likelihood of developing newCMBs in deep brain
regions and not with CMBs only in lobar areas. The observed
associations are present even after controlling for demographics,
cardiovascular risk factors, APOE e4 allele, and markers of ce-
rebral SVD (e.g., prevalent CMBs, subcortical infarcts, and
WMLs). Given the underlying presumed etiopathology of
CMBs by location, this suggests that pure geographic atrophy
and load of retinal microvascular lesions may be useful markers
of different underlying pathologies in the brain.
The association between AMD and an increased risk of clinical
stroke has been reported in several population-based cohort
studies.25,26 In this cohort study, we examined the longitudinal
associations of retinal microvascular signs and macular de-
generation with CMBs by anatomic location. Our findings
suggest a new hypothesis that pure geographic atrophy subtype
of AMD may be associated with processes also regulating ce-
rebral neurodegeneration, insofar as CAA, which is caused by
amyloid deposits in the lobar microvessels, does.1,4 It is worth
noting that the prevalence of pure geographic atrophy in our
sample was only 1.12%, so results should be interpreted with
caution.
However, the far more prevalent hypertension is the major risk
factor for retinal arteriolar signs and retinopathy lesions, as well as
for cerebrovascular disease ranging from clinical stroke and sub-
clinical brain lesions (e.g., lacunar infarcts, WMLs, and CMBs) to
progression of cerebral SVD.9,27–29 Our study showed that the
more retinal microvascular signs present, the higher the like-
lihood of developing new CMBs in deep brain areas, not in
strictly lobar regions. This pattern of association is in line with
a hospital-based study30 that showed that retinal focal arteriolar
narrowing and arteriovenous nicking were less common in
patients with lobar intracerebral hemorrhage than in thosewith
deep intracerebral hemorrhage, a sequelae of CMBs.1,2
The pathophysiologic mechanisms underlying the associations
of retinal microvascular signs and geographic atrophy with
region-specific CMBs are not fully understood, but studies of
the etiopathophysiology of this association are emerging. First,
retinal arteriolar signs and deep CMBs share common
Table 2 Association between AMD and incident CMBs by anatomic location (n = 2,484)
AMD
Global CMBs (n = 456) Exclusively lobar CMBs (n = 290)a Deep CMBs (n = 166)a
No. Odds ratio (95% CI)b No. Odds ratio (95% CI)b No. Odds ratio (95% CI)b
No AMD (n = 1,941) 352 1.00 (Reference) 219 1.00 (Reference) 133 1.00 (Reference)
Early AMD (n = 451) 84 0.90 (0.68–1.20) 54 0.96 (0.68–1.34) 30 0.82 (0.53–1.26)
Late AMD (n = 92) 20 0.95 (0.55–1.67) 17 1.40 (0.76–2.56) 3 0.34 (0.10–1.16)
Exudative AMD (n = 63) 11 0.70 (0.34–1.45) 10 1.11 (0.52–2.40) 1 0.16 (0.02–1.19)
Pure geographic atrophy (n = 29) 9 1.91 (0.80–4.56) 7 2.59 (1.01–6.65) 2 0.96 (0.20–4.49)
Abbreviations: AMD = age-related macular degeneration; CI = confidence interval; CMB = cerebral microbleed.
a Participants with no incident CMBs (n = 2,028) were held as a referent group for multinomial logistic modeling when the associations with incident CMBs by
anatomic location (i.e., exclusively lobar or deep CMBs vs no CMBs) were examined.
b Odds ratio (95%CI) was adjusted for age, sex, types of coils, follow-up interval, current smoking, systolic blood pressure, use of antihypertensive drugs, body
mass index, diabetes mellitus, total cholesterol, baseline prevalent CMBs, subcortical infarcts, volume of white matter lesions, and APOE e4 allele.
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cardiovascular risk factors, especially hypertension.6 Second, dis-
ruption of the blood-retina barrier from retina hypoxia owing
to long-term exposures to cardiovascular risk factors, which is
analogous to and correlated with the blood-brain barrier dys-
function, may play a part in the pathogenesis of both retinal
microvascular lesions and cerebral microangiopathy.30,31 Fi-
nally, evidence has emerged that β-amyloid, as a hallmark of
Alzheimer pathology and CAA in the brain,32,33 also exists in
the retina and the heart of patients with AD.34–36 Given the
homology of microvasculature in the brain and the retina and
the involvement of β-amyloid in both retinal degeneration
(AMD) and CAA,10,12,37,38 the link of pure geographic atrophy
with strictly lobar CMBs may reflect underlying pathologic
processes common in both the brain and the retina. Given that
experimental and clinical studies have shown amyloid deposits
in the retina, the hypothesis of neurodegenerative-like process
in AMD is of interest to follow up in populations in which the
prevalence of pure geographic atrophy or, in reverse, AD is
higher than in our cohort.
Strengths of this study include the prospective nature of the study
design, the community-derived large cohort of older adults, and
control of multiple potential confounders, including markers of
cerebral SVD. Furthermore, theMRI sequences and definition of
CMBs used in our study were comparable to those in the
recommended standard scales (e.g., Microbleed Anatomical
Rating Scale [MARS] and Brain Observer MicroBleed Scale
[BOMBS]).1 Our study also has limitations. First, the analytic
sample was younger and healthier than those excluded, which
may potentially bias our estimates. Second, a potential limi-
tation of the retinal microvascular index was that the 3 retinal
microvascular signs might reflect different stages of retinal
microvascular alterations. However, the composite index of
retinal microvascular profile may be more stable than the in-
dividual retinal makers because single retinal microvascular
signs may fluctuate as a result of transient metabolic and he-
modynamic alterations.39 Finally, statistical power was limited
for the analysis of certain subgroups (e.g., deep CMBs in
late AMD).
Overall, our findings suggest that additional studies are nec-
essary to explore common pathophysiologic processes of mi-
crovascular damage and neurodegeneration in the retina and
the brain. In combination with additional biological and
functional information, it may be possible in the future to
develop retinal screening algorithms for brain disease and to
identify elderly people at high risk for CMBs and related
functional consequences.
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Table 3 Association between retinal microvascular signs and incident CMBs by anatomic location (n = 2,497)
Retinal microvascular signs
Global CMBs (n = 461) Exclusively lobar CMBs (n = 293)a Deep CMBs (n = 168)a
No. Odds ratio (95% CI)b No. Odds ratio (95% CI)b No. Odds ratio (95% CI)b
Focal arteriolar narrowing
Absence (n = 2,365) 423 1.00 (Reference) 272 1.00 (Reference) 151 1.00 (Reference)
Presence (n = 132) 38 1.55 (1.03–2.34) 21 1.42 (0.85–2.36) 17 1.91 (1.08–3.39)
Arteriovenous nicking
Absence (n = 2,060) 369 1.00 (Reference) 253 1.00 (Reference) 116 1.00 (Reference)
Presence (n = 437) 92 1.06 (0.80–1.38) 40 0.67 (0.46–0.97) 52 1.96 (1.36–2.84)
Retinopathy lesions
Absence (n = 2,212) 392 1.00 (Reference) 253 1.00 (Reference) 139 1.00 (Reference)
Presence (n = 285) 69 1.33 (1.00–1.88) 40 1.26 (0.86–1.79) 29 1.49 (0.98–2.27)
Index of retinal microvascular signsc
0 (n = 1,782) 305 1.00 (Reference) 211 1.00 (Reference) 94 1.00 (Reference)
1 (n = 585) 116 1.03 (0.80–1.32) 64 0.83 (0.61–1.13) 52 1.48 (1.02–2.14)
≥2 (n = 130) 40 1.76 (1.16–2.69) 18 1.21 (0.70–2.09) 22 3.00 (1.73–5.20)
p for trend 0.047 0.760 <0.001
Abbreviations: CI = confidence interval; CMB = cerebral microbleed.
a Participants with no incident CMBs (n = 2,036) were held as a referent group for multinomial logistic modeling when the associations with incident CMBs by
anatomic location (i.e., exclusively lobar or deep CMBs vs no CMBs) were examined.
b Odds ratio (95%CI) was adjusted for age, sex, types of coils, follow-up interval, current smoking, systolic blood pressure, use of antihypertensive drugs, body
mass index, diabetes mellitus, total cholesterol, baseline prevalent CMBs, subcortical infarcts, volume of white matter lesions, and APOE e4 allele.
c The composite index (range 0–3) was computed by counting the 3 retinal microvascular signs (i.e., retinal focal arteriolar narrowing, arteriovenous nicking,
and retinopathy lesions) concurrently present in the participant.
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Are age-related macular degeneration (AMD) and retinal
microvascular signs differentially associated with lobar and
deep cerebral microbleeds (CMBs)?
Summary answer
In older people, retinal microvascular signs are associated with
deep CMBs. Pure geographic atrophy, a form of AMD, is
associated exclusively with lobar CMBs.
What is known and what this paper adds
Retinal microvascular signs are associated with brain
lesions and infarcts. AMD is a potential neurodegenerative
biomarker. We elucidated how AMD and retinal micro-
vascular signs are associated with CMBs in specific brain
areas.
Participants and setting
We examined 2,502 Icelandic Age, Gene/Environment Sus-
ceptibility (AGES)-Reykjavik Study participants born in 1907
to 1935.
Design, size, and duration
Participants were examined in 2002 to 2006 and 2007 to
2011. Both examinations included brain MRI scans, which
permitted CMB assessments, and fundus photography,
which permitted assessments of AMD and retinal micro-
vascular signs (i.e., focal arteriolar narrowing, arteriove-
nous nicking, and retinopathic lesions). Collected images
were analyzed automatically or by evaluators blinded to
participant identities. Binomial logistic models were
used to calculate odds ratios (ORs) for CMBs, and multi-
nomial logistic models were used to assess how AMD and
retinal microvascular signs were associated with CMB
locations.
Main results and the role of chance
Over the follow-up period (mean 5.2 ± 0.2 years), new
CMBs were detected in 461 (18.43%) participants. Pure
geographic atrophy was associated with increased risk of
new CMBs (OR 1.91, 95% confidence interval [CI]
0.80–4.56), particularly exclusively lobar CMBs (OR 2.59,
95% CI 1.01–6.65). Each additional observed retinal mi-
crovascular sign was associated with increased risk of new
CMBs (p for trend = 0.047), especially deep CMBs (p for
trend < 0.001).
Bias, confounding, and other reasons
for caution
The low prevalence of pure geographic atrophy noted
(1.12%) is a reason for caution. The participants inclu-
ded were younger and healthier than the excluded par-
ticipants. The 3 analyzed retinal microvascular signs
may reflect different stages of retinal microvascular alter-
ations. Statistical power was limited for some subgroup
analyses.
Generalizability to other populations
Because we examined a large and well-established cohort, the
results are probably generalizable to similar populations.
Study funding/potential competing interests
This study was supported by the NIH, the Icelandic Heart
Association, and the Icelandic government. Dr. Cotch serves
on the editorial boards of 2 journals. Dr. Qiu has received
Swedish Research Council grants. Go to Neurology.org/N for
full disclosures.
OR (95% CI) for
exclusively lobar CMBs
OR (95% CI) for
deep CMBs
Early AMD vs no AMD 0.96 (0.68–1.34) 0.82 (0.53–1.26)
Late AMD vs no AMD 1.40 (0.76–2.56) 0.34 (0.10–1.16)
Presence of a retinal
microvascular sign
0.83 (0.61–1.13) 1.48 (1.02–2.14)
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